The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TARS | +54.73% | +165.21% | +21.54% | +247% |
| S&P | +18.54% | +92.9% | +14.04% | +94% |
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $102.66M | 151.5% |
| Gross Profit | $96.42M | 155.0% |
| Gross Margin | 93.92% | 1.3% |
| Market Cap | $1.70B | 65.7% |
| Market Cap / Employee | $5.27M | 0.0% |
| Employees | 323 | 32.4% |
| Net Income | -$20.34M | 38.9% |
| EBITDA | -$21.73M | 34.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $96.65M | -46.6% |
| Accounts Receivable | $58.33M | 97.5% |
| Inventory | 3.9 | 76.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $72.13M | 0.8% |
| Short Term Debt | $0.32M | -47.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -21.10% | 31.9% |
| Return On Invested Capital | -30.42% | -6.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$30.39M | -96.8% |
| Operating Free Cash Flow | -$29.39M | -104.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.96 | 8.91 | 8.77 | 4.97 | 33.25% |
| Price to Sales | 9.74 | 11.67 | 8.65 | 5.81 | -52.91% |
| Price to Tangible Book Value | 5.03 | 9.24 | 9.11 | 5.09 | 34.60% |
| Enterprise Value to EBITDA | -40.94 | -79.88 | -65.28 | -64.76 | 175.70% |
| Return on Equity | -59.6% | -54.8% | -34.0% | -31.5% | -58.08% |
| Total Debt | $72.34M | $72.45M | $72.37M | $72.45M | 0.36% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
